Impact of JAK-inhibition on pain and biphasic P2X7R expression on CD4+ T cells in experimental arthritis
Jérôme Biton, Roxane Hervé, Magali Breckler, Delphine Lemeiter, Patrice Decker, Johanna Sigaux, Eric Assier, Luca Semerano, Natacha Bessis, Marie-Christophe Boissier, Elodie Rivière · 2026
Read Impact of JAK-inhibition on pain and biphasic P2X7R expression on CD4+ T cells in experimental arthritis by Jérôme Biton, Roxane Hervé, Magali Breckler, Delphine Lemeiter, Patrice Decker, Johanna Sigaux, Eric Assier, Luca Semerano, Natacha Bessis, Marie-Christophe Boissier, Elodie Rivière (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13421492.txt.
Description
Jerome Biton and colleagues tested arthritis pain relief in 2026 in mice, comparing a JAK inhibitor, baricitinib, with an anti-TNF drug, etanercept, in collagen-induced arthritis. Pain remains a major unmet need in rheumatoid arthritis. The purinergic receptor P2X7R may drive inflammatory pain, so the team tracked pain tests, joint damage, and receptor levels by treatment timing.
Both drugs eased joint inflammation and damage, and both relieved pain when given late, while P2X7R on helper T cells rose with early baricitinib and fell with late treatment. The paper points pain research toward timing-dependent receptor changes as a clue to why arthritis pain persists.
Catalog record
| CREATOR | Jérôme Biton, Roxane Hervé, Magali Breckler, Delphine Lemeiter, Patrice Decker, Johanna Sigaux, Eric Assier, Luca Semerano, Natacha Bessis, Marie-Christophe Boissier, Elodie Rivière |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |